Most work on GRPR-targeted compounds has been done in prostate cancer (PCa), as GRPR is overexpressed in the majority of PCa lesions [3], particularly in early, androgen-dependent stages of PCa [4], but also in late-stage neuroendocrine PCa [5], which could be addressing tumors with absent or low PSMA expression. This evidence concerns the gene FOLH1 and posterior cortical atrophy.